COVID-19 updates, including vaccine information, for our patients and visitors Learn More

Menu
Search

CIRM Awards $5 Million Early Translational Grant to UC San Diego Researcher

 

April 30, 2009  |  

A stem cell researcher from the University of California, San Diego, Yang Xu, professor of biology, has been awarded a $5.16 million grant from the California Institute for Regenerative Medicine (CIRM).  Fifteen Early Translational grants, totaling $67.7 million, were approved at the April 29 meeting of the Independent Citizens’ Oversight Committee to fund work that translates basic research into clinical cures.

“This Early Translational grant will enable Dr. Xu and researchers at UC San Diego to develop improved models of human disease,” said Larry Goldstein, PhD, director of UC San Diego’s Stem Cell Program. “Our hope is that these models will provide scientists and biotech companies with more reliable ways to test drugs for safety and efficacy.”

Xu’s research uses induced pluripotent stem cells (iPSCs), which are very similar to human embryonic stem cells (hESCs). Generated from a patient’s somatic cells, pre-existing cells that no longer differentiate, iPSCs could provide an ideal cell source for transplantation by avoiding graft rejection in the patient.  Xu and colleagues propose to eliminate the cancer risk associated with pluripotent stem cells and develop mouse models with a functional human immune system in order to study immune responses and tolerance during cell transplantation. 

“This new translational grant will allow us to establish extensive collaboration with other physician scientists to solve the issues of cancer risk and immune rejection associated with pluripotent stem cell-based therapy,” said Xu.

The latest round of CIRM funding brings the total grants to the UC San Diego Stem Cell Program to close to $45 million since grants were first awarded in late 2005. 

###

Media Contact: Debra Kain, 619-543-6163, ddkain@ucsd.edu




Media Contact

Share This Article


Related News

8/2/2021
UC San Diego researchers modify remdesivir, creating oral version that can be taken earlier in COVID-19 diagnoses. In cell and animal studies, revised drug proved effective and safe.
7/28/2021
Obesity is a major public health issue among Latinos, and a risk factor for Alzheimer’s disease. But in a new study, researchers at UC San Diego report that cardiometabolic abnormalities, such as hype ...
7/28/2021
Cardiovascular physicians with UC San Diego Health have joined an international clinical trial utilizing a new Extravascular Implantable Cardioverter-Defibrillator (EV ICD) system to help treat sudden ...
7/26/2021
UC San Diego Health, the region’s only academic health system, is ranked #1 in San Diego and #5 in California, placing it among the nation’s best hospitals, according to the 2021-2022 U.S. News & Worl ...



Follow Us